Form 4: Opus Genetics COO Executes Automatic Stock Sale

Chief Operating Officer Joseph K. Schachle sold 4,697 shares of Opus Genetics to cover tax obligations related to RSU vesting.

Summary

• Joseph K. Schachle, Chief Operating Officer of Opus Genetics, Inc., sold 4,697 shares of common stock.
• The transaction occurred on April 23, 2026, at a price of $5.2202 per share.
• Following the transaction, the reporting person retains beneficial ownership of 296,084 shares.
• The sale was executed automatically to satisfy tax withholding obligations resulting from the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was mandatory for tax purposes rather than a discretionary market move.

Positives

• The transaction was non-discretionary, indicating it was not a signal of management's outlook on the company's future performance.

Negatives

• Reduction in direct equity holdings by a key executive.

Risks

• None identified; this is a routine tax-related transaction.

Future Outlook

Not applicable; this filing relates to a historical transaction for tax purposes.

Management Comments

• The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard corporate practice for executives to manage tax liabilities associated with equity compensation and do not typically reflect changes in management sentiment.

Comparison to Industry Standards

• The transaction aligns with standard industry practices for executive equity management.
• Automatic tax withholding sales are common among publicly traded biotechnology firms to manage RSU settlement.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and limited in volume.

Next Steps

• None identified.

Key Dates

Keywords

Opus Genetics, IRD, Insider Trading, Form 4, Executive Compensation, Tax Withholding